News coverage about Conatus Pharmaceuticals (NASDAQ:CNAT) has been trending somewhat negative recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a news impact score of -0.01 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.8674215810086 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Short Interest in Conatus Pharmaceuticals Inc. (CNAT) Declines By 30.6% (americanbankingnews.com)
- Short Interest Decreases By 30.6% For CNAT (thestreet.com)
- Endo International plc (ENDP) is at $6.09 per share and Conatus Pharmaceuticals Inc. (CNAT) is listed at $4.07 – Stocks Gallery (stocksgallery.com)
- Conatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.60) Per Share (americanbankingnews.com)
- Conatus to Present at Stifel Healthcare Conference (finance.yahoo.com)
Shares of Conatus Pharmaceuticals (NASDAQ CNAT) opened at $4.08 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.69 and a quick ratio of 2.69. Conatus Pharmaceuticals has a 12 month low of $1.73 and a 12 month high of $9.40.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The firm had revenue of $9.57 million during the quarter, compared to the consensus estimate of $16.06 million. During the same period in the previous year, the firm earned ($0.31) EPS. sell-side analysts predict that Conatus Pharmaceuticals will post -0.65 EPS for the current year.
CNAT has been the topic of a number of research analyst reports. Stifel Nicolaus reissued a “buy” rating and issued a $10.00 price target on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. Seaport Global Securities reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective (down previously from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Conatus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $16.00.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.